Rheumatoid Arthritis

Drug shows promise treating chronic and potentially life-threatening skin disease.

Researchers evaluate the benefits of subcutaneous methotrexate compared with the oral version.

Two different dose prescriptions achieve similar results.

Treatment seeks to teach the immune system to ignore a peptide that leads to inflammation.

Researchers seek to improve treatment for autoimmune diseases, including rheumatoid arthritis, gout, Crohn's disease, and lupus.

Rheumatoid arthritis treatment remains consistently well tolerated over long-term evaluation.

Biologics are changing how clinicians make treatment choices.

A number of barriers found in smoking cessation.

Study suggests rheumatoid arthritis chronicity can be influenced.

New treatment approach many help control inflammation.

Researchers explore the use of probiotics to alter communication between brain and immune system.

Compound shows promise in reducing a precursor to RA.

Lithium chloride found to slow degradation.

Researchers study excess fluid from swollen joints of rheumatoid arthritis.

Methotrexate alone superior in efficacy to combination treatment with DMARDs.

Low dose methotrexate more likely to cause infectious adverse events than higher doses of the same drug.

Pfizer executive discusses the present and future of biosimilars.

Research ongoing to target treatment-resistant gout.

Stem cells have been found to target inflammation in osteoarthritis or rheumatoid arthritis.

Lower inflammation scores found in patients with RA receiving statins.

Xeljanz treat adults with moderate to severe active RA who have had an inadequate response or intolerance to methotrexate.

The FDA is reviewing a once-daily formulation of Pfizer's tofacitinib citrate (Xeljanz) for rheumatoid arthritis (RA).

Productivity and absenteeism improved in patients with chronic inflammatory arthritides.

Treating patients within 3 months of the onset of symptoms may prove to be beneficial.

Patients achieve drug-free remission with less expensive biologic drugs during first 2 years of treatment.